Anatomical Pathology Market size was valued at USD 18,739.5 million in 2021 and is poised to grow at a significant CAGR of 8.3% over 2022–2028. The widespread use of modern pathology technology, such as staining systems, gross imaging, and digital microscopes, is expected to improve anatomic pathological techniques significantly. Digital imaging options outperform traditional procedures in terms of specificity and accuracy, increasing the market for anatomic pathology services. Furthermore, the industry is driven by various partnerships and agreement ventures among significant firms to introduce an effective portfolio. For example, in April 2021, Royal Philips partnered with Ibex Medical Analytics, a business specializing in AI-based cancer diagnoses, to promote AI-based digital pathology adoption. Both organizations merged their knowledge to provide pathologists with enhanced solutions. Also, in oncology drug trials, anatomic pathology products and services are utilized to assess quantitative data, discover morphological structures, detect pharmacodynamic markers, and better comprehend drug processes. It’s also used to divide trial participants into groups depending on tissue reactions to medicines.Tissue diagnostics make trials and retrospective investigations more efficient by lowering the cost and time. The PD-L1 (programmed death-ligand 1) expression was measured using an experimental immunohistochemistry (IHC) test developed by Roche Tissue Diagnostics in a Phase III study for Roche’s cancer immunotherapy, TECENTRIQ (atezolizumab). Furthermore, the instruments category is expected to develop due to ongoing technological advancements and targeted efforts by market competitors to produce anatomic pathological instruments with superior designs. For example, Precision Instruments released the CF-6100 cryostat in April 2020. This cryostat encourages and supports tissue sectioning in dermatology, histology, and pathology. Diagnostic laboratories have benefited from improved testing equipment and technology, which has offered significant expansion opportunities. Similarly, the expansion of the research laboratory sector has been aided by a high number of clinical studies carried out as part of numerous ongoing initiatives. With the overall goal of achieving a high level of patient satisfaction, the research laboratory is committed to providing timely and complete information regarding the function of sick tissues.
Recent Market Developments:
In May 2021, Hologic received premarket approval (PMA) from the FDA for its ThinPrep GenesisTM processor for cytology processing and specimen transfer for downstream applications.
In May 2021, a digital pathology solutions provider-OptraSCAN introduced CytoSiA-an intelligent solution for affordable and rapid scanning and analysis of pap smears and liquid-based cytology slides. This instrument allows whole slide cytology imaging with advanced image analysis.